Cadrenal Therapeutics, Inc. Common Stock Total Liabilities
Cadrenal Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, Cadrenal Therapeutics, Inc. Common Stock (CVKD) has total liabilities worth $1.06 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See CVKD defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Cadrenal Therapeutics, Inc. Common Stock (2022–2025)
Total liabilities of Cadrenal Therapeutics, Inc. Common Stock from 2022 to 2025. This chart illustrates how Cadrenal Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Cadrenal Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Cadrenal Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Glen Burnie Bancorp
NASDAQ:GLBZ
|
USA | $373.70 Million |
|
1CM INC.
F:IQ70
|
Germany | €10.29 Million |
|
Firefly Neuroscience, Inc.
NASDAQ:AIFF
|
USA | $2.75 Million |
|
Flour Mills Kepenos S.A.
AT:KEPEN
|
Greece | €45.05 Million |
|
Jocil Limited
NSE:JOCIL
|
India | Rs799.08 Million |
|
Logisys Inc
KQ:067730
|
Korea | ₩9.08 Billion |
|
Telefast Indonesia
JK:TFAS
|
Indonesia | Rp42.65 Billion |
|
S. Pack & Print Public Company Limited
BK:SPACK
|
Thailand | ฿559.96 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down Cadrenal Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CVKD current and non-current assets.
Liquidity & Leverage Metrics
Cadrenal Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained
Cadrenal Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cadrenal Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cadrenal Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Cadrenal Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.59 Million | -40.83% |
| 2024-12-31 | $2.68 Million | +224.59% |
| 2023-12-31 | $826.88K | -86.94% |
| 2022-12-31 | $6.33 Million | -- |
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with… Read more